Venrock Healthcare Capital Partners Iii, L.p. - Net Worth and Insider Trading

Venrock Healthcare Capital Partners Iii, L.p. Net Worth

The estimated net worth of Venrock Healthcare Capital Partners Iii, L.p. is at least $235 Million dollars as of 2024-11-29. Venrock Healthcare Capital Partners Iii, L.p. is the 10% Owner of Constellation Pharmaceuticals Inc and owns about 4,016,873 shares of Constellation Pharmaceuticals Inc (CNST) stock worth over $137 Million. Venrock Healthcare Capital Partners Iii, L.p. is the 10% Owner of KalVista Pharmaceuticals Inc and owns about 4,824,731 shares of KalVista Pharmaceuticals Inc (KALV) stock worth over $49 Million. Venrock Healthcare Capital Partners Iii, L.p. is also the 10% Owner of Altimmune Inc and owns about 4,500,000 shares of Altimmune Inc (ALT) stock worth over $39 Million. Besides these, Venrock Healthcare Capital Partners Iii, L.p. also holds Cogent Biosciences Inc (COGT) . Details can be seen in Venrock Healthcare Capital Partners Iii, L.p.'s Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Venrock Healthcare Capital Partners Iii, L.p. has not made any transactions after 2024-02-08 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Venrock Healthcare Capital Partners Iii, L.p.

Venrock Healthcare Capital Partners Iii, L.p. Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Venrock Healthcare Capital Partners Iii, L.p. owns 7 companies in total, including Cogent Biosciences Inc (COGT) , Altimmune Inc (ALT) , and Constellation Pharmaceuticals Inc (CNST) among others .

Click here to see the complete history of Venrock Healthcare Capital Partners Iii, L.p.’s form 4 insider trades.

Insider Ownership Summary of Venrock Healthcare Capital Partners Iii, L.p.

Ticker	Comapny	Transaction Date	Type of Owner
COGT	Cogent Biosciences Inc	2020-08-18	10 percent owner
ALT	Altimmune Inc	2021-02-25	10 percent owner
CNST	Constellation Pharmaceuticals Inc	2019-12-13	10 percent owner
		2018-09-05	10 percent owner
		2024-02-08	10 percent owner
		2022-06-01	10 percent owner
		2022-04-06	10 percent owner

Venrock Healthcare Capital Partners Iii, L.p. Latest Holdings Summary

Venrock Healthcare Capital Partners Iii, L.p. currently owns a total of 4 stocks. Among these stocks, Venrock Healthcare Capital Partners Iii, L.p. owns 4,016,873 shares of Constellation Pharmaceuticals Inc (CNST) as of December 13, 2019, with a value of $137 Million and a weighting of 58.12%. Venrock Healthcare Capital Partners Iii, L.p. owns 4,824,731 shares of KalVista Pharmaceuticals Inc (KALV) as of February 8, 2024, with a value of $49 Million and a weighting of 20.72%. Venrock Healthcare Capital Partners Iii, L.p. also owns 4,500,000 shares of Altimmune Inc (ALT) as of June 15, 2020, with a value of $39 Million and a weighting of 16.72%. The other 1 stocks Cogent Biosciences Inc (COGT) have a combined weighting of 4.44% among all his current holdings.

Latest Holdings of Venrock Healthcare Capital Partners Iii, L.p.

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
CNST	Constellation Pharmaceuticals Inc	2019-12-13	4,016,873	33.99	136,533,513
KALV	KalVista Pharmaceuticals Inc	2024-02-08	4,824,731	10.09	48,681,536
ALT	Altimmune Inc	2020-06-15	4,500,000	8.73	39,285,000
COGT	Cogent Biosciences Inc	2020-08-18	1,088,818	9.58	10,430,876

Holding Weightings of Venrock Healthcare Capital Partners Iii, L.p.

Venrock Healthcare Capital Partners Iii, L.p. Form 4 Trading Tracker

According to the SEC Form 4 filings, Venrock Healthcare Capital Partners Iii, L.p. has made a total of 1 transactions in Constellation Pharmaceuticals Inc (CNST) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Constellation Pharmaceuticals Inc is the acquisition of 400,000 shares on December 13, 2019, which cost Venrock Healthcare Capital Partners Iii, L.p. around $14 Million.

According to the SEC Form 4 filings, Venrock Healthcare Capital Partners Iii, L.p. has made a total of 9 transactions in KalVista Pharmaceuticals Inc (KALV) over the past 5 years, including 9 buys and 0 sells. The most-recent trade in KalVista Pharmaceuticals Inc is the acquisition of 86,048 shares on February 8, 2024, which cost Venrock Healthcare Capital Partners Iii, L.p. around $1 Million.

According to the SEC Form 4 filings, Venrock Healthcare Capital Partners Iii, L.p. has made a total of 2 transactions in Altimmune Inc (ALT) over the past 5 years, including 2 buys and 0 sells. The most-recent trade in Altimmune Inc is the acquisition of 1,500,000 shares on June 15, 2020, which cost Venrock Healthcare Capital Partners Iii, L.p. around $11 Million.

More details on Venrock Healthcare Capital Partners Iii, L.p.'s insider transactions can be found in the Insider Trading History of Venrock Healthcare Capital Partners Iii, L.p. table.

Insider Trading History of Venrock Healthcare Capital Partners Iii, L.p.

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Venrock Healthcare Capital Partners Iii, L.p. Trading Performance

GuruFocus tracks the stock performance after each of Venrock Healthcare Capital Partners Iii, L.p.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Venrock Healthcare Capital Partners Iii, L.p. is 2.86%. GuruFocus also compares Venrock Healthcare Capital Partners Iii, L.p.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Venrock Healthcare Capital Partners Iii, L.p. within 3 months outperforms 2 times out of 13 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Venrock Healthcare Capital Partners Iii, L.p.'s insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Venrock Healthcare Capital Partners Iii, L.p.

Average Return

Average return per transaction

Outperforming Transactions

2 out of 4 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	29.12
Relative Return to S&P 500(%)	25.77

Venrock Healthcare Capital Partners Iii, L.p. Ownership Network

Ownership Network List of Venrock Healthcare Capital Partners Iii, L.p.

No Data

Ownership Network Relation of Venrock Healthcare Capital Partners Iii, L.p.

Venrock Healthcare Capital Partners Iii, L.p. Owned Company Details

What does Cogent Biosciences Inc do?

Who are the key executives at Cogent Biosciences Inc?

Venrock Healthcare Capital Partners Iii, L.p. is the 10 percent owner of Cogent Biosciences Inc. Other key executives at Cogent Biosciences Inc include 10 percent owner & other: See Remarks Fairmount Funds Management Llc , Chief Legal Officer Evan Kearns , and Chief Financial Officer John L. Green .

Cogent Biosciences Inc (COGT) Insider Trades Summary

Over the past 18 months, Venrock Healthcare Capital Partners Iii, L.p. made no insider transaction in Cogent Biosciences Inc (COGT). Other recent insider transactions involving Cogent Biosciences Inc (COGT) include a net purchase of 800,000 shares made by Fairmount Funds Management Llc ,

In summary, during the past 3 months, insiders sold 0 shares of Cogent Biosciences Inc (COGT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Cogent Biosciences Inc (COGT) were sold and 800,000 shares were bought by its insiders, resulting in a net purchase of 800,000 shares.

Cogent Biosciences Inc (COGT)'s detailed insider trading history can be found in Insider Trading Tracker table.

Cogent Biosciences Inc Insider Transactions

No Available Data

What does Altimmune Inc do?

Who are the key executives at Altimmune Inc?

Venrock Healthcare Capital Partners Iii, L.p. is the 10 percent owner of Altimmune Inc. Other key executives at Altimmune Inc include Chief Financial Officer Richard I Eisenstadt , Chief Medical Officer Matthew Scott Harris , and Chief Business Officer Raymond M Jordt .

Altimmune Inc (ALT) Insider Trades Summary

Over the past 18 months, Venrock Healthcare Capital Partners Iii, L.p. made no insider transaction in Altimmune Inc (ALT). Other recent insider transactions involving Altimmune Inc (ALT) include a net sale of 15,711 shares made by David Drutz ,

In summary, during the past 3 months, insiders sold 0 shares of Altimmune Inc (ALT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 16,011 shares of Altimmune Inc (ALT) were sold and 300 shares were bought by its insiders, resulting in a net sale of 15,711 shares.

Altimmune Inc (ALT)'s detailed insider trading history can be found in Insider Trading Tracker table.

Altimmune Inc Insider Transactions

No Available Data

What does Constellation Pharmaceuticals Inc do?

Who are the key executives at Constellation Pharmaceuticals Inc?

Venrock Healthcare Capital Partners Iii, L.p. is the 10 percent owner of Constellation Pharmaceuticals Inc. Other key executives at Constellation Pharmaceuticals Inc include Chief Financial Officer Emma Reeve , 10 percent owner Column Group L P , and See Remarks Karen Valentine .

Constellation Pharmaceuticals Inc (CNST) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Constellation Pharmaceuticals Inc (CNST) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Constellation Pharmaceuticals Inc (CNST) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Constellation Pharmaceuticals Inc (CNST)'s detailed insider trading history can be found in Insider Trading Tracker table.

Constellation Pharmaceuticals Inc Insider Transactions

No Available Data

What does Bellerophon Therapeutics Inc do?

Who are the key executives at Bellerophon Therapeutics Inc?

Venrock Healthcare Capital Partners Iii, L.p. is the 10 percent owner of Bellerophon Therapeutics Inc. Other key executives at Bellerophon Therapeutics Inc include 10 percent owner Puissance Life Science Opportunities Fund Vi , VP of Business Operations Parag Suresh Shah , and See Remarks Martin Dekker .

Bellerophon Therapeutics Inc (BLPH) Insider Trades Summary

Over the past 18 months, Venrock Healthcare Capital Partners Iii, L.p. made no insider transaction in Bellerophon Therapeutics Inc (BLPH). Other recent insider transactions involving Bellerophon Therapeutics Inc (BLPH) include a net sale of 1,076,841 shares made by Puissance Life Science Opportunities Fund Vi , and a net sale of 134,421 shares made by Puissance Capital Fund (gp) Llc .

In summary, during the past 3 months, insiders sold 0 shares of Bellerophon Therapeutics Inc (BLPH) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 1,211,262 shares of Bellerophon Therapeutics Inc (BLPH) were sold and 0 shares were bought by its insiders, resulting in a net sale of 1,211,262 shares.

Bellerophon Therapeutics Inc (BLPH)'s detailed insider trading history can be found in Insider Trading Tracker table.

Bellerophon Therapeutics Inc Insider Transactions

No Available Data

What does KalVista Pharmaceuticals Inc do?

Who are the key executives at KalVista Pharmaceuticals Inc?

Venrock Healthcare Capital Partners Iii, L.p. is the 10 percent owner of KalVista Pharmaceuticals Inc. Other key executives at KalVista Pharmaceuticals Inc include Chief Medical Officer Paul K. Audhya , Chief Development Officer Christopher Yea , and CFO and Secretary Benjamin L Palleiko .

KalVista Pharmaceuticals Inc (KALV) Insider Trades Summary

Over the past 18 months, Venrock Healthcare Capital Partners Iii, L.p. made 9 insider transaction in KalVista Pharmaceuticals Inc (KALV) with a net purchase of 1,251,017. Other recent insider transactions involving KalVista Pharmaceuticals Inc (KALV) include a net sale of 155,123 shares made by Benjamin L Palleiko , a net sale of 95,977 shares made by Christopher Yea , and a net sale of 63,847 shares made by Paul K. Audhya .

In summary, during the past 3 months, insiders sold 41,171 shares of KalVista Pharmaceuticals Inc (KALV) in total and bought 0 shares, with a net sale of 41,171 shares. During the past 18 months, 600,355 shares of KalVista Pharmaceuticals Inc (KALV) were sold and 1,251,017 shares were bought by its insiders, resulting in a net purchase of 650,662 shares.

KalVista Pharmaceuticals Inc (KALV)'s detailed insider trading history can be found in Insider Trading Tracker table.

KalVista Pharmaceuticals Inc Insider Transactions

No Available Data

What does Tricida Inc do?

Who are the key executives at Tricida Inc?

Venrock Healthcare Capital Partners Iii, L.p. is the 10 percent owner of Tricida Inc. Other key executives at Tricida Inc include director & 10 percent owner Orbimed Advisors Llc , director & 10 percent owner David P Bonita , and 10 percent owner Venrock Healthcare Capital Partners Ii, L.p. .

Tricida Inc (TCDAQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Tricida Inc (TCDAQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Tricida Inc (TCDAQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Tricida Inc (TCDAQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Tricida Inc Insider Transactions

No Available Data

What does Vistagen Therapeutics Inc do?

Who are the key executives at Vistagen Therapeutics Inc?

Venrock Healthcare Capital Partners Iii, L.p. is the 10 percent owner of Vistagen Therapeutics Inc. Other key executives at Vistagen Therapeutics Inc include Chief Operating Officer Joshua S. Prince , CHIEF FINANCIAL OFFICER Cynthia Lynn Anderson , and 10 percent owner Commodore Capital Lp .

Vistagen Therapeutics Inc (VTGN) Insider Trades Summary

Over the past 18 months, Venrock Healthcare Capital Partners Iii, L.p. made no insider transaction in Vistagen Therapeutics Inc (VTGN). Other recent insider transactions involving Vistagen Therapeutics Inc (VTGN) include a net purchase of 775,756 shares made by Commodore Capital Lp ,

In summary, during the past 3 months, insiders sold 0 shares of Vistagen Therapeutics Inc (VTGN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Vistagen Therapeutics Inc (VTGN) were sold and 775,756 shares were bought by its insiders, resulting in a net purchase of 775,756 shares.

Vistagen Therapeutics Inc (VTGN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Vistagen Therapeutics Inc Insider Transactions

No Available Data

Venrock Healthcare Capital Partners Iii, L.p. Mailing Address

Above is the net worth, insider trading, and ownership report for Venrock Healthcare Capital Partners Iii, L.p.. You might contact Venrock Healthcare Capital Partners Iii, L.p. via mailing address: 530 Fifth Avenue, 22nd Floor, New York Ny 10036.

Discussions on Venrock Healthcare Capital Partners Iii, L.p.

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.